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doi:10.1016/j.ejvs.2010.09.017 Abstract Objectives: To investigate the outcomes of thoracic endovascular aortic repair (TE-
VAR) for ruptured descending thoracic aortic aneurysm (rDTAA) in patients older than 75 years. 
Methods: We retrospectively identiﬁed all patients treated with TEVAR for rDTAA at seven 
referral centres between 2002 and 2009. The cohort was stratiﬁed according to age 75 and 
>75 years, and the outcomes after TEVAR were compared between both groups. 
Results: Ninety-two patients were identiﬁed of which 73% (n Z 67) were 75 years, and 27% 
(n Z 25) were older than 75 years. The 30-day mortality was 32.0% in patients older than 75 
years, and 13.4% in the remaining patients (p Z 0.041). Patients older than 75 years suffered 
more frequently from postoperative stroke (24.0% vs. 1.5%, p Z 0.001) and pulmonary compli­
cations (40.0% vs. 9.0%, p Z 0.001). The aneurysm-related survival after 2 years was 52.1% for 
patients >75 years, and 83.9% for patients 75 years (p Z 0.006). 
Conclusions: Endovascular treatment of rDTAA in patients older than 75 years is associated 
with an inferior outcome compared with patients younger than 75 years. However, the 
mortality and morbidity rates in patients above 75 years are still acceptable. These results 
may indicate that endovascular treatment for patients older than 75 years with rDTAA is worth­
while. 
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49 Endovascular Treatment of Ruptured Thoracic Aortic Aneurysm in Patients Older than 75 Years Age is a strong risk factor for mortality and morbidity after for an endovascular approach, open surgery is offered or surgical intervention for acute aortic disease.1e11 Ruptured 
descending thoracic aortic aneurysm (rDTAA) is a rare but 
life-threatening aortic pathology requiring immediate 
intervention.11e13 Traditional open thoracic aortic surgery 
typically involves thoracotomy and aortic cross-clamping, 
procedures that are poorly tolerated, especially by elderly 
patients. Because of the extremely high mortality rates,11 
some institutions do not offer open surgical repair to very 
elderly patients admitted with rDTAA. Thoracic endovas­
cular aortic repair (TEVAR) is a minimally invasive technique, 
which is increasingly used for the management of acute 
thoracic aortic pathologies, and endovascular methods are 
replacing the open surgical approach for the management of 
rDTAA. As a result of the less-invasive characteristics of 
TEVAR, increasing age may have a less-signiﬁcant impact on 
the results of endovascular management of rDTAA. 
We have previously reported about our experience with 
endovascular management of rDTAA.14 Because the results 
were not stratiﬁed for age, the exact outcome of elderly 
patients with rDTAA is unclear, and it remains uncertain if 
offering TEVAR to rDTAA patients older than 75 years is still 
worthwhile. The purpose of the present multicentre study 
is to investigate the outcomes of endovascular treatment 
for rDTAA in patients above 75 years. Methods 
Study population 
For this observational study, we retrospectively identiﬁed all 
patients who were treated with TEVAR for rDTAA between 
January 2001 and July 2009 at the Yale New Haven Hospital 
(New Haven, CT, USA), Baylor College of Medicine, (Houston, 
TX, USA), University of Florida (Gainesville, FL, USA), Poli­
clinico San Donato IRCCS (San Donato Milanese, Italy), 
St. Antonius Hospital (Nieuwegein, The Netherlands), Eras­
mus University Medical Center (Rotterdam, The 
Netherlands) and the University Medical Center Utrecht 
(Utrecht, The Netherlands). All ruptured aneurysms that 
were located between the left subclavian artery and the 
celiac axis and treated with TEVAR were included. Ruptured 
aneurysm was deﬁned as any disruption of the aneurysmal 
aortic wall with an extravascular collection of blood. 
Ruptured dissected aneurysms were included only if the 
aortic diameter was larger than 50 mm. 
Endovascular repair has become the preferred treatment 
over the years for the management of descending thoracic 
aortic disease at the participating institutions. All endovas­
cular procedures were performed in the operating room 
under general anaesthesia by vascular and/or cardiothoracic 
surgeons. Prophylactic cerebrospinal ﬂuid drainage was only 
performed if the patient was at increased risk for spinal cord 
ischaemia, including extensive aortic coverage or TEVAR 
after previous abdominal aortic intervention. Revascular­
isation of the left subclavian artery or the use of heparin 
depended on the surgeon’s preference. Current contraindi­
cations for TEVAR include no proximal or distal aortic neck, 
or a neck diameter that is too wide for commercially avail­
able thoracic endografts. If the aortic anatomy is unsuitable treatment is refused. 
The cohort of rDTAA patients was stratiﬁed according to 
age 75 and >75 years, and presentation, procedural char­
acteristics and outcomes after TEVAR were compared 
between both groups. The STrengthening the Reporting of 
OBservational studies in Epidemiology (STROBE) guidelines for 
observational studies were used for the design of the present 
study and report.15 The study was approved by the institu­
tional review committee at all participating institutions. End points and statistical analysis 
The following outcome variables were compared between 
patients 75 and >75 years: mortality, major complications 
including stroke, paraplegia/paraparesis, cardiac compli­
cations, pulmonary complications, acute renal failure, 
bleeding, aortic re-intervention and a composite of these 
major adverse events. Categorical variables were 
compared between patients 75 and >75 years using the 
chi-square test. Continuous variables with an approxi­
mately normal distribution were investigated using the 
Student’s t-test; other continuous variables were explored 
using the ManneWhitney U test. Multivariate logistic 
regression analysis was used to investigate independent 
effects of age >75 years and other baseline and operating 
characteristics on the 30-day mortality. Age >75 years, 
gender and variables with a P value <0.2 in univariate 
analysis were integrated into the multivariate regression 
model. KaplaneMeier survival analysis was used to inves­
tigate the aneurysm-related survival and all-cause survival 
for patients 75 and >75 years during 2 years of follow-up. 
Aneurysm-related death was deﬁned as death within 30 
days or death after 30 days due to complications related to 
the aneurysm and/or intervention. Statistical analysis was 
performed using Statistical Package for Social Sciences 
(SPSS) 15.0 software; a P value < 0.05 was considered 
statistically signiﬁcant. 
Results 
Patient and operating characteristics 
Ninety-two patients underwent TEVAR for rDTAA, the mean 
age of the cohort was 69.4 years and 73% (n Z 67) were 75 
years and 27% (n Z 25) were >75 years (Fig. 1). A history of 
hypertension (83% vs. 46%, p Z 0.002) and hyperlipidemia 
(46% vs. 21%, p Z 0.030) was more common in the elderly 
cohort (Table 1). Hypovolaemic shock at admission was 
present in 33% of the patients >75 years, compared with 
18% of the patients 75 years (p Z 0.117). There were no 
differences in operating characteristics between both 
groups (Table 2). 
Early outcomes 
Overall, 17.4% (n Z 16) of the cohort expired within the 
ﬁrst month. The 30-day mortality was 32.0% in patients 
older than 75 years, and 13.4% in the remaining patients 
(odds ratio (OR) 3.0, 95% conﬁdence interval (CI) 1.1e10.6, 
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Figure 1 Distribution of age. Overall, 73% (n Z 67) were 75 
years, and 27% (n Z 25) were older than 75 years. p Z 0.041). Among the elderly cohort, the 30-day mortality 
was 41.7% for patients older than 80 years (5 of 12), and 
23.1% for patients between 75 and 80 years (3 of 13, 
p Z 0.319). 
Major postoperative complications (including death) 
occurred in 72.0% of patients older than 75 years, and in 
35.8% of the patients 75 years (OR 4.6, 95% CI 1.7e12.6, 
p Z 0.002). Patients older than 75 years suffered more 
frequently from periprocedural stroke (24.0% vs. 1.5%, 
p Z 0.001) and pulmonary complications (40.0% vs. 9.0%, 
p Z 0.001, Table 3). The median length of stay was 14.0 
days for the elderly cohort, compared with 7.0 days for 
patients 75 years (p Z 0.024). 
Multivariate regressions analysis conﬁrmed that age 
above 75 years was an independent predictor of 30-day 
mortality after TEVAR (OR 3.7, 95% CI 1.02e13.9, p Z Table 1 Baseline characteristics. 
75 years 
N (%) 
Demographics 
Mean age (y) 65.4 (11
Male gender 46 (68.7
Patient History 
Hypertension 29 (46.0
Diabetes Mellitus 9 (14.5
Hyperlipidemia 13 (21.3
CAD 27 (44.3
COPD 14 (21.5
CRI 8 (13.1
Carotid disease 8 (13.1
Prior aortic intervention 13 (19.4
Presentation 
Aneurysm diameter (mm) 53.7 (21
Hypovolaemic shock 12 (17.9
Contained rupture 26 (38.8
Associated dissection 11 (16.4
CAD: coronary artery disease, COPD: chronic obstructive pulmonary di
CSF: cerebrospinal ﬂuid. Hypovolaemic shock was deﬁned as a heart
and a mean arterial pressure <90 mm Hg. 0.047). Other independent predictors of 30-day mortality 
were hypovolaemic shock (OR 5.3, 95% CI 1.41e18.2, 
p Z 0.013) and hemothorax at admission (OR 5.0, 95% CI 
1.13e22.6, p Z 0.034, Table 4). 
Midterm outcomes 
The median length of follow-up of patients who were alive 
at 30 days was 13.5 months. Five additional patients died 
during follow-up of complications related to the aneurysm 
and/or intervention, including an infected endograft and/ 
or sepsis (n Z 3), aortic rupture (n Z 1) and a poor general 
condition (n Z 1). The aneurysm-related survival after 2 
years was 52.1% for patients >75 years, and 83.9% for 
patients 75 years (p Z 0.006, Fig. 2). Nine additional 
patients died during follow-up of causes unrelated to the 
ruptured aneurysms, including myocardial infarction 
(n Z 5), stroke (n Z 1) and unknown (n Z 3). The all-cause 
survival after 2 years was 28.9% for patients >75 years, and 
71.8% for the younger cohort (p Z 0.001, Fig. 3). 
Overall, thoracic aortic re-interventions were required 
in 11 patients after TEVAR, of which seven were 75 years, 
and four were >75 years. The median time interval 
between the initial endovascular procedure was and the re-
intervention was 17 days, and 64% (n Z 7) of the re-inter­
ventions were performed during the ﬁrst month after 
TEVAR (Table 3). 
Discussion 
Acute aortic syndromes are generally associated with high 
mortality and morbidity rates, and risks of surgery for 
acute aortic disease are dramatically increased in elderly 
patients.1e11 The exact outcome of elderly patients 
with rDTAA undergoing TEVAR has been less well deﬁned >75 years P value 
N (%) 
) 80.5 (2.6) <0.001 
) 16 (64.0) 0.67 
) 19 (82.6) 0.003 
) 2 (9.1) 0.51 
) 10 (45.5) 0.030 
) 11 (50.0) 0.64 
) 8 (34.8) 0.21 
) 5 (23.8) 0.24 
) 5 (22.7) 0.28 
) 5 (20.8) 0.88 
) 56.4 (17) 0.61 
) 8 (33.3) 0.12 
) 5 (22.7) 0.17 
) 2 (8.3) 0.33 
sease, CRI: chronic renal insufﬁciency. LSA: left subclavian artery, 
 rate 120 beats/minute, a respiratory rate 30 breaths/minute 
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Table 2 Procedural characteristics. 
75 years >75 years P value 
N (%) N (%) 
TEVAR within 24 h 55 (82.1) 22 (91.7) 0.27 
Mean graft diameter (mm) 37.6 (3.6) 37.0 (4.2) 0.54 
Total graft length (mm) 150.6 (124) 150.7 (88) 0.99 
Coverage LSA 23 (34.3) 8 (33.3) 0.93 
CSF drainage 13 (19.4) 4 (16.7) 0.77 
TEVAR after 2006 42 (62.7) 17 (68.0) 0.64 
LSA: left subclavian artery, CSF: cerebrospinal ﬂuid. 
Table 3 Early outcomes. 
Variable 75 years >75 years OR 95% CI P value 
N (%) N (%) 
30-day mortality 8 (11.9) 8 (32.0) 3.5 1.1e10.6 0.024 
Major complications 24 (35.8) 18 (72.0) 4.6 1.7e12.6 0.002 
Stroke 1 (1.5) 6 (24.0) 20.8 2.4e83.9 0.001 
Paraplegia/paraparesis 6 (9.0) 1 (4.0) 0.42 0.05e3.7 0.43 
Cardiac complications 3 (4.5) 2 (8.0) 1.9 0.29e11.8 0.51 
Pulmonary complications 6 (9.0) 10 (40.0) 6.8 2.1e21.6 0.001 
Acute renal failure 5 (7.5) 3 (12.0) 1.7 0.37e7.7 0.49 
Bleeding 6 (9.0) 4 (16.0) 1.9 0.50e7.5 0.33 
Aortic re-intervention 4 (6.0) 3 (12.0) 2.2 0.45e10.4 0.33 
Other re-interventions 19 (28.4) 7 (28.0) 0.98 0.35e2.7 0.97 
trapped lung tissue. 
 
OR: odds ratio, CI: conﬁdence interval. Major complications included death, stroke, paraplegia/paraparesis, cardiac complications, 
pulmonary complications, acute renal failure, bleeding, and aortic re-intervention. Other re-interventions included placement of 
a thorax drain (n Z 22), esophagostomy (n Z 3) and a thoracotomy (n Z 1) for evacuation of a clotted hemothorax and release of because ruptured aneurysms of the thoracic aorta are less 
common than rAAA,12,16 and TEVAR is a relatively novel 
treatment option. In this evaluation, we observed that the 
overall outcomes of TEVAR for rDTAA are encouraging. In 
rDTAA patients older than 75 years, however, the mortality 
was signiﬁcantly increased, and a multivariable regression 
model conﬁrmed that age >75 years was an independent 
predictor of death. A logical explanation for the high 
mortality among the elderly cohort may be that such 
patients typically have a poor general condition, with 
more cardiovascular risk factors (Table 1), resulting in 
increased surgical risks. Diagnosed or undiagnosed 
atherosclerosis of the carotid and cerebral arteries likely 
was  more common in the  patients  older than  75 years,
resulting in a very high incidence of periprocedural stroke, Table 4 Independent predictors of 30-day mortality. 
OR 
Age >75 3.7 
Female gender 0.9 
Prior aortic intervention 1.9 
Hemothorax 5.0 
Hypovolaemic shock 5.3 
Aortic dissection 2.2 
OR: odds ratio, CI: conﬁdence interval. a potentially lethal complication. A higher risk of stroke in 
elderly patients has been observed as well for other 
interventions using endovascular devices in the aortic 
arch, such as carotid artery stenting.17 
Because of the poor outcomes of the very elderly 
patients with acute thoracic aortic disease, some institu­
tions do not offer surgical intervention to them. Although 
we observed substantially increased mortality and 
morbidity in patients older than 75 years, we believe that 
the outcomes of TEVAR for rDTAA were still acceptable in 
our evaluation. Based on these results, endovascular repair 
with rDTAA appears an appropriate treatment for patients 
above 75 years, if the procedure is performed by a team 
with adequate endovascular experience. The mortality rate 
did differ considerably for the patients between 75 and 80 95%CI P value 
1.02e13.9 0.047 
0.21e3.50 0.81 
0.91e7.74 0.29 
1.13e22.6 0.034 
1.41e18.2 0.013 
0.52e11.2 0.25 
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Figure 2 Aneurysm-related survival for patients  and >75 
years. The aneurysm-related survival after 2 years was 52.1% 
for patients >75 years, and 83.9% for patients 75 years. years, and those who were older than 80 years. For the 
latter, over 40% of patients expired within 30 days. The 
beneﬁts of an endovascular intervention in the very elderly 
patients remain therefore more questionable; however, 
strong conclusions cannot be drawn due to the limited 
number of patients in this subgroup. 
The results of traditional open surgery for elderly rDTAA 
patients are thought to be inferior compared with patients 
managed with endovascular repair. Schermerhorn and 
colleagues found an overall in-hospital mortality rate of 
52.4% for rDTAA patients older than 75 years using the 
National Impatient Sample (NIS) database from 1988 to 
2003,11 which is considerably higher than the early 
mortality rate here reported. However, the decision to 
offer open surgery, TEVAR or no treatment to a very elderly 
patient with rDTAA should be based on individual patient 
characteristics and the expertise of the operator or insti­
tution. Several classiﬁcations and scores have been Figure 3 All-cause survival for patients  and >75 years. The 
all-cause survival after 2 years was only 28.9% for patients >75 
years and 71.8% for patients 75 years. developed, including the Acute Physiology and Chronic 
Health Evaluation (APACHE) II score, the Glasgow Aneurysm 
Score (GAS) and the American Society of Anaesthesiologists 
(ASA) Classiﬁcation, to estimate the risk of death of 
admitted patients.18e21 These parameters may be used as 
well for assessing the operative risks for an rDTAA patient 
requiring urgent intervention. In addition, surgical 
mortality rates are generally lower if the intervention is 
performed by high-volume surgeons in a high-volume 
hospital.22,23 All seven participating hospitals were referral 
centres that have signiﬁcant expertise and experience with 
TEVAR, limiting the applicability of these results to centres 
that lack such capability. 
This study has several strengths as well as limitations. 
Because our cohort of rDTAA patients treated with TEVAR is 
currently the largest available series, it offers a unique 
opportunity to analyse the outcomes of the subset of 
patients with an age above 75 years. However, the sample 
size of this elderly subgroup (n Z 25) remains relatively 
small for adequate analysis. Furthermore, data were 
collected retrospectively, and subject to incomplete or 
missing reporting of events. Finally, we did not include 
a control arm of rDTAA patients above 75 years treated with 
open surgery because TEVAR has emerged as the preferred 
approach at our institutions. 
Conclusion 
Age predicts mortality and morbidity in patients affected 
by rDTAA treated with TEVAR. Endovascular treatment of 
rDTAA in patients older than 75 years is associated with an 
inferior outcome compared with patients younger than 75 
years. However, the mortality and morbidity rates in 
patients above 75 years are still acceptable. These results 
may indicate that endovascular treatment for patients 
older than 75 years with rDTAA is worthwhile. 
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